Studies have shown that SNPs in the CYP19A1, such as rs6493497 and rs7176005, are linked to higher baseline aromatase activity in postmenopausal breast cancer patients undergoing neoadjuvant AI therapy [43]. The gene discussed is CYP19A1; the disease is breast cancer.